Theriva Biologics, Inc.

What they do

Theriva Biologics is a diversified clinical-stage company focused on oncology, with lead candidate VCN-01 (zabilugene almadenorepvec), a modified oncolytic adenovirus designed for intravenous and intravitreal delivery to kill tumor cells and enhance anti-tumor immune response. It is being evaluated in a Phase 2b trial (VIRAGE) for pancreatic cancer, a Phase 1 trial for retinoblastoma, and other studies. The company also holds SYN-004 (ribaxamase) and SYN-020 (intestinal alkaline phosphatase) assets, though SYN-020 has been out-licensed and SYN-004 is being explored for out-licensing.

Revenue drivers

• VCN-01 — Lead oncology candidate, no commercial revenue; potential future Phase 3 pivotal trial in metastatic pancreatic ductal adenocarcinoma.
• SYN-020 license — Out-licensed to Rasayana in February 2026, which assumes all development costs; potential milestone payments but no current revenue.
• SYN-004 (ribaxamase) — GI asset being explored for out-licensing or partnership; no current revenue.
• Grant funding — Received $1.6 million from Spanish government R&D rebate program in January 2026; not a recurring revenue stream.

Recent performance

For the three months ended June 30, 2026, revenue was $300,000 (likely grant or license income). Cash and equivalents were $11.3 million as of June 30, 2026, with a cash runway into Q1 2027. Net losses were $25.7 million in 2024 and $23.7 million in 2025, with operating cash flow of -$16.7 million in 2025. The company has a going concern note from its auditor due to recurring losses and net capital deficiency.

Strategy

Theriva is concentrating on oncology, focusing on VCN-01 development and business development/licensing activities. Management plans to run a Phase 3 pivotal trial in metastatic PDAC following positive FDA feedback on trial design. They are also evaluating a repeated dosing regimen (VIRAGE2) and seeking to advance retinoblastoma to a Phase 2/3 trial. The company reduced workforce by 32% in September 2025 to cut costs and extend cash runway, while exploring value from SYN-004 via licensing.

Risks

• Going concern risk — Auditor has raised substantial doubt about ability to continue as a going concern without additional capital.
• Clinical trial failure — VCN-01 is still in clinical trials and may fail to show efficacy or safety in Phase 3 or other studies.
• Limited cash runway — Cash of $11.3 million only funds into Q1 2027, and may not be sufficient to complete large pivotal trials without additional financing.
• Dependence on partnership — SYN-004 development is halted without grant funding or partnership; SYN-020 licensing may not generate meaningful returns.

Outlook

Management expects VIRAGE2 enrollment to complete in H2 2026, with initial data anticipated by Q3 2027. They plan to discuss the retinoblastoma Phase 2/3 protocol with the FDA in Q3 2026. The company anticipates extending cash runway into Q1 2027, but notes cash may only cover certain clinical trials.